CORCencora
Is it growing?
Neither accelerating nor breaking down: nothing decisive, though earnings up +38% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +10% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 0.9% now against 0.9% a year earlier.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is COR growing?
Cencora has grown revenue 9.4% a year over three years and 10% a year over five, with earnings per share compounding at 18%.
Revenue growth, 3-year annual rate · Healthcare median +11% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +10%
Revenue growth, 5-year rate · +9.4% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +18%
Earnings per share, 3-year rate · revenue +9.4% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 19
Years of annual history on file · FY2007 to FY2025, as filed
Details›
- Revenue FY2021
- $214.0B
- Revenue FY2022
- $238.6B
- Revenue FY2023
- $262.2B
- Revenue FY2024
- $294.0B
- Revenue FY2025
- $321.3B
Annual income statements as filed with the SEC.